Akermin is a US based company.
While at Dow he had responsibility for technology development in all of Dow’s industrial biotechnology activities. He was formerly a member of the board of directors of Neoprobe Corporation and the Biotechnology Research and Development Corporation, as well as the scientific advisory board of zuChem. He currently consults with several early stage bio-based materials companies. Dr. Dowd received his Ph.D. in 1970 in physical-organic chemistry from Indiana University.
“Bill brings a wealth of experience and knowledge to Akermin’s development activities for the commercialization of our proprietary enzyme stabilization technologies,” said Barry Blackwell, president and chief executive officer of Akermin. “His insight and guidance will be an invaluable resource as we advance our technology.”
